Please amend claims 20, 22, 25, 27-29, 33-34, 36-38, 41-43, 46, 50, 52, 54-55, 57, 60, 63, and 65-66 to read as follows:

A2

20. (Amended) A method for enhancing the delivery of a drug through the skin of a mammal, comprising contacting epithelial cells of a mammal with a cell adhesion modulating agent and a drug, wherein said modulating agent comprises

(a) the sequence His-Ala-Val, or

(b) an antibody or fragment thereof that specifically binds to a cadherin cell adhesion recognition sequence,

wherein said modulating agent inhibits cadherin-mediated cell adhesion, and wherein the step of contacting is performed under conditions and for a time sufficient to allow passage of said drug across said epithelial cells.

A3

22. (Amended) A method according to claim 20, wherein said modulating agent passes into the blood stream of said mammal.

A4

25. (Amended) A method according to claim 20, wherein said modulating agent further comprises at least one cell adhesion recognition sequence bound by an adhesion molecule other than a classical cadherin, and wherein said cell adhesion recognition sequence is separated from any His-Ala-Val sequence(s) by a linker.

A5

27. (Amended) A method according to claim 20, wherein said modulating agent is linked to a targeting agent.

28. (Amended) A method according to claim 20, wherein said modulating agent is linked to said drug.

29. (Amended) A method according to claim 20, wherein said modulating agent is present within a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

A6

33. (Amended) A method according to claim 20, wherein the step of contacting is performed via a skin patch comprising said modulating agent and said drug.

34. (Amended) A method for enhancing the delivery of a drug to a tumor in a mammal, comprising administering to a mammal a cell adhesion modulating agent and a drug, wherein said modulating agent comprises

(a) 3-16 amino acid residues, including the sequence His-Ala-Val, or

(b) an antibody or fragment thereof that specifically binds to a cadherin cell adhesion recognition sequence,

and wherein said modulating agent inhibits cadherin-mediated cell adhesion.

A7

36. (Amended) A method according to claim 34, wherein the tumor is selected from the group consisting of bladder tumors, ovarian tumors and melanomas.

37. (Amended) A method according to claim 34, wherein said composition is administered to said tumor.

38. (Amended) A method according to claim 34, wherein said composition is administered systemically.

A8

41. (Amended) A method according to claim 34, wherein said modulating agent is linked to a targeting agent.

42. (Amended) A method according to claim 34, wherein said modulating agent linked to said drug.

43. (Amended) A method according to claim 34, wherein said modulating agent further comprises one or more of:

(a) a cell adhesion recognition sequence bound by an adhesion molecule other than a classical cadherin, wherein said cell adhesion recognition sequence is separated from any His-Ala-Val sequence(s) by a linker; and/or

(b) an antibody or antigen-binding fragment thereof that binds to a cell adhesion recognition sequence bound by an adhesion molecule other than a classical cadherin.

46. (Amended) A method according to claim 33, wherein said modulating agent and said drug are present within a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

50. (Amended) A method for treating cancer in a mammal, comprising administering to a mammal a cell adhesion modulating agent, wherein said modulating agent comprises

(a) 3-16 amino acid residues, including the sequence His-Ala-Val, or

(b) an antibody or fragment thereof that specifically binds to a cadherin cell adhesion recognition sequence,

and wherein said modulating agent inhibits cadherin-mediated cell adhesion.

52. (Amended) A method according to claim 50, wherein said cancer is selected from the group consisting of carcinomas, leukemia and melanomas.

54. (Amended) A method according to claim 50, wherein said modulating agent is linked to a targeting agent.

55. (Amended) A method according to claim 50, wherein said modulating agent further comprises at least one cell adhesion recognition sequence bound by an adhesion molecule other than a classical cadherin, and wherein said cell adhesion recognition sequence is separated from any His-Ala-Val sequence(s) by a linker.

A13

57. (Amended) A method according to claim 50, wherein said modulating agent is present within a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

A14

60. (Amended) A method for inhibiting angiogenesis in a mammal, comprising administering to a mammal a cell adhesion modulating agent, wherein said modulating agent comprises

(a) the sequence His-Ala-Val,

(b) an antibody or fragment thereof that specifically binds to a cadherin cell adhesion recognition sequence,

and wherein said modulating agent inhibits cadherin-mediated cell adhesion.

A15

63. (Amended) A method according to claim 60, wherein said modulating agent further comprises at least one cell adhesion recognition sequence bound by an adhesion molecule other than a classical cadherin, and wherein said cell adhesion recognition sequence is separated from any His-Ala-Val sequence(s) by a linker.

A16

65. (Amended) A method according to claim 60, wherein said modulating agent is linked to a target agent.

66. (Amended) A method according to claim 60, wherein said modulating agent is present within a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

REMARKS

Claims 1-191 were previously pending. With this amendment, claims 1-19, 21, 35, 51, 62, 69-188, and 190-192 are canceled. Accordingly, claims 20, 22-34, 36-50, 52-61, 63-68 and 189 are currently pending. Claims 20, 22, 25, 27-29, 33-34, 36-38, 41-43, 46, 50, 52, 54-